cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1166Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESКлиническая фармакогенетика блокаторов рецепторов ангиотензина II: новые возможности индивидуализации фармакотерапии?Clinical pharmacogenetics of angiotensin II receptor blockers: new perspectives of pharmacotherapy individualizationСычевД. А.SychevD. A.vera_bel_05@mail.ruАникинГ. С.AnikinG. S.vera_bel_05@mail.ruБелолипецкаяВ. Г.BelolipetskayaV. G.vera_bel_05@mail.ruИгнатьевИ. В.IgnatyevI. B.vera_bel_05@mail.ruКукесВ. Г.KukesV. G.vera_bel_05@mail.ruИнститут клинической фармакологии НЦ «ЭСМП» Росздравнадзора; Московская медицинская академия им. И.М. СеченоваClinical Pharmacology Institute, Scientific Center for Medical Agents Expertise, Federal Supervising Service in Health and Social Development; I.M. Sechenov Moscow Medical AcademyФГУ «Государственный научно-исследовательский центр профилактической медицины Росздрава», МоскваState Research Center for Preventive Medicine, Russian Federal Agency of Health and Social Development. Moscow20062004200652100105Copyright © Сычев Д.А., Аникин Г.С., Белолипецкая В.Г., Игнатьев И.В., Кукес В.Г., 20062006Сычев Д.А., Аникин Г.С., Белолипецкая В.Г., Игнатьев И.В., Кукес В.Г.Sychev D.A., Anikin G.S., Belolipetskaya V.G., Ignatyev I.B., Kukes V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1166

Обзор посвящен перспективам применения фармакогенетических исследований блокаторов рецептора ангиотензина II (БРА) в клинической практике. Рассмотрены результаты исследований влияния полиморфизма генов системы биотрансформации (CYP2C9) и ренин-ангиотензин-альдостероновой системы на фармакокинетику и фармакодинамику БРА. Рассматриваемые фармакогенетические исследования были выполнены не только у здоровых добровольцев, но и у больных артериальной гипертензией и хронической сердечной недостаточностью. 

The review focuses on clinical practice perspectives for angiotensin II receptor blockers (ARB). The authors discuss the results of the trials on biotransformation genes (CYP2C9) polymorphism and renin-angiotensin-aldosterone system influence on ARB pharmacokinetics and pharmacodynamics. Pharmacogenetic studies have been performed not only in healthy volunteers, but also in patients with arterial hypertension or chronic heart failure.

фармакогенетикафармакокинетикаблокаторы рецептора ангиотензина IICYP2C9I/D полиморфизм ангиотензин-превращающего ферментаParmacogeneticspharmacokineticsangiotensin II receptor blockersCYP2C9I/D ACE polymorphismReferencesКукес В.Г. Метаболизм лекарственных средств: клиникофармакологические аспекты. Москва «Реафарм» 2004; 18- 27, 40-7.Кукес В.Г. Метаболизм лекарственных средств: клиникофармакологические аспекты. Москва «Реафарм» 2004; 18- 27, 40-7.Лильин Е.Т., Богомазов Е.А., Гофман-Кадошников П.Б. Генетика для врача. Москва «Медицина» 1990; 176-87.Лильин Е.Т., Богомазов Е.А., Гофман-Кадошников П.Б. Генетика для врача. Москва «Медицина» 1990; 176-87.Середенин С.Б. Лекции по фармакогенетике. Москва «МИА» 2004; 303 с.Середенин С.Б. Лекции по фармакогенетике. Москва «МИА» 2004; 303 с.Соради И. Основы и педиатрические аспекты фармакогенетики. Будапешт. Изд-во Академии наук Венгрии 1984; 248 с.Соради И. Основы и педиатрические аспекты фармакогенетики. Будапешт. Изд-во Академии наук Венгрии 1984; 248 с.Сычев Д.А. Клиническая фармакогенетика. Клиническая фармакология под ред. Академика РАМН, проф. Кукеса В.Г. Москва «ГЕОТАР-МЕД» 2004.Сычев Д.А. Клиническая фармакогенетика. Клиническая фармакология под ред. Академика РАМН, проф. Кукеса В.Г. Москва «ГЕОТАР-МЕД» 2004.Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76(2): 113-8.Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76(2): 113-8.Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111(25): 3374-83. Epub 2005 Jun 20.Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111(25): 3374-83. Epub 2005 Jun 20.Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60(5): 337-42. Epub 2004 Jun 10.Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60(5): 337-42. Epub 2004 Jun 10.Conrady AO, Kiselev IO, Usachev NI, et al. Effect of 24- week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res 2005; 33(Suppl 1): 30A-8.Conrady AO, Kiselev IO, Usachev NI, et al. Effect of 24- week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res 2005; 33(Suppl 1): 30A-8.Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20(10): 2089-93.Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20(10): 2089-93.Heller S, Linhart A, Jindra A, et al. Association of -344/T/ C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press 2004; 13(3): 158-63.Heller S, Linhart A, Jindra A, et al. Association of -344/T/ C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press 2004; 13(3): 158-63.Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61(9): 627-34.Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61(9): 627-34.Rodgers JE, Patterson JH. Angiotensin II-Receptor Blockers: Clinical Relevance and Therapeutic Role. Am J Health-Syst Pharm 2001; 58(8): 671-83.Rodgers JE, Patterson JH. Angiotensin II-Receptor Blockers: Clinical Relevance and Therapeutic Role. Am J Health-Syst Pharm 2001; 58(8): 671-83.Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15(5): 389-93.Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15(5): 389-93.Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. AJH 2004; 17: 8-13.Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. AJH 2004; 17: 8-13.Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20(4): 657-63.Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20(4): 657-63.Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19(10): 1783-7.Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19(10): 1783-7.Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23(6): 720-5.Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23(6): 720-5.Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445(1-2): 151-2.Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445(1-2): 151-2.Pharmacogenomics/ edited by Rothstein M.A. Willy-liss. New Jersey 2003; 368 p.Pharmacogenomics/ edited by Rothstein M.A. Willy-liss. New Jersey 2003; 368 p.Redon J, Luque-Otero M, Martell N, Chaves FJ; POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5(1): 14-20.Redon J, Luque-Otero M, Martell N, Chaves FJ; POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5(1): 14-20.Sekino K, Kubota T, Okada Y, et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59(8-9): 589-92.Sekino K, Kubota T, Okada Y, et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59(8-9): 589-92.Sookoian S, Castano G, Garcia SI, et al. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol 2005; 100(3): 636-42.Sookoian S, Castano G, Garcia SI, et al. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol 2005; 100(3): 636-42.Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005; 23(4): 753-8.Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005; 23(4): 753-8.Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57(10): 729-35.Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57(10): 729-35.Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Рharmacol Ther 2002; 71: 89-98.Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Рharmacol Ther 2002; 71: 89-98.Weekers L, Bouhanick B, Hadjadj S, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. Diabetes 2005; 54(10): 2961-7.Weekers L, Bouhanick B, Hadjadj S, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. Diabetes 2005; 54(10): 2961-7.

The authors declare that there are no conflicts of interest present.